Brain Cancer - Pipeline Review, H2 2012


#135334

347pages

Global Markets Direct

$ 2000

In Stock


Brain Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Brain Cancer Pipeline Review, H2 2012', provides an overview of the Brain Cancer therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. 'Brain Cancer Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Brain Cancer.
  • A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Brain Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Brain Cancer therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Brain Cancer Therapeutic Products under Development, Key Players in Brain Cancer Therapeutics, Brain Cancer Pipeline Overview, Brain Cancer Pipeline, Brain Cancer Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Brain Cancer Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Brain Cancer 12
Brain Cancer Therapeutics under Development by Companies 14
Brain Cancer Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 23
Comparative Analysis 23
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Discovery and Pre-Clinical Stage Products 26
Comparative Analysis 26
Brain Cancer Therapeutics Products under Development by Companies 27
Brain Cancer Therapeutics Products under Investigation by Universities/Institutes 29
Companies Involved in Brain Cancer Therapeutics Development 39
United Therapeutics Corporation 39
Sanofi-Aventis 40
Eli Lilly and Company 41
Novartis AG 42
Dong-A Pharmaceutical Co., Ltd. 43
Nippon Shinyaku Co., Ltd. 44
Pfizer Inc. 45
Alfacell Corporation 46
Advaxis, Inc. 47
Neuralstem, Inc. 48
Lixte Biotechnology Holdings, Inc. 49
Bionomics Limited 50
Critical Outcome Technologies Inc. 51
Prana Biotechnology Limited 52
Diamyd Medical AB 53
e-Therapeutics plc 54
AngioChem Inc. 55
Pervasis Therapeutics, Inc. 56
PTC Therapeutics, Inc. 57
Stemline Therapeutics, Inc. 58
Kinex Pharmaceuticals, LLC 59
to-BBB technologies BV 60
Archer Biosciences, Inc 61
ArmaGen Technologies, Inc. 62
VectorLogics, Inc. 63
Brain Cancer Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Combination Products 65
Assessment by Route of Administration 66
Assessment by Molecule Type 69
Drug Profiles 72
NC3 - Drug Profile 72
Bafetinib - Drug Profile 73
BSI-201 - Drug Profile 75
COTI-2 - Drug Profile 77
AC 03-636 - Drug Profile 78
8H9 MAb - Drug Profile 79
SL-302 - Drug Profile 80
SL-301 - Drug Profile 81
SL-301 - Drug Profile 82
DA-3607 - Drug Profile 83
2.5-Dimethyl-Celecoxib - Drug Profile 84
Vorinostat + Bevacizumab + Temozolomide - Drug Profile 85
ADXS-HER2 - Drug Profile 86
CST-102 - Drug Profile 87
PTC-299 - Drug Profile 88
Valproate + Etoposide - Drug Profile 90
Bortezomib + Temozolomide - Drug Profile 91
AdV-tk + Valacyclovir + Radiation Therapy - Drug Profile 92
BNC105 - Drug Profile 93
ETS2101 - Drug Profile 94
Melphalan - Drug Profile 96
Topotecan - Drug Profile 97
Temozolomide + Lapatinib - Drug Profile 98
Melphalan - Drug Profile 99
Combination Therapy for Brain and Central Nervous System Tumors - Drug Profile 100
Thalidomide + Temozolomide - Drug Profile 101
Rapamycin - Drug Profile 102
Bevacizumab - Drug Profile 103
Topotecan - Drug Profile 105
Aminolevulinic acid - Drug Profile 106
Aminolevulinic acid - Drug Profile 107
Busulfan - Drug Profile 108
Melphalan + Mannitol - Drug Profile 109
Carmustine + O(6)-Benzylguanine - Drug Profile 110
Imatinib Mesylate - Drug Profile 111
Temsirolimus + Perifosine - Drug Profile 112
Sprycel + Temozolomide + Radiation Therapy - Drug Profile 113
Oral Topotecan + Temozolomide - Drug Profile 115
PXD101 + PS-341 - Drug Profile 117
Topotecan - Drug Profile 118
Rituximab + Methotrexate - Drug Profile 119
Bortezomib + Temozolomide - Drug Profile 120
Abraxane + Lapatinib - Drug Profile 122
AC480 for Recurrent Glioma - Drug Profile 124
Temozolomide + Thiotepa + Carboplatin + 13-Cis-Retinoic Acid + Autologous Stem Cell Rescue - Drug Profile 125
Etoposide + Cyclophosphamide + Thalidomide + Celecoxib + Fenofibrate - Drug Profile 127
Radiation Therapy + Temozolomide - Drug Profile 129
Chlorotoxin + Iron Oxide Nano Particles - Drug Profile 131
Temozolomide + Radiation Therapy + Bevacizumab - Drug Profile 132
Bevacizumab + Temozolomide + Radiation Therapy - Drug Profile 134
RIP1 - Drug Profile 136
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile 137
PT-100 + Temozolomide - Drug Profile 140
PT-100 + Carboplatin - Drug Profile 142
cediranib maleate - Drug Profile 144
Erlotinib Hydrochloride - Drug Profile 145
O6-Benzylguanine + Temozolomide + Filgrastim - Drug Profile 147
Carboplatin + Cyclophosphamide + Etoposide + Vincristine - Drug Profile 148
Carboplatin + Cisplatin + Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Vincristine - Drug Profile 150
Cisplatin + Cyclophosphamide + Vincristine Sulfate + Radiation Therapy + Autologous Stem Cell Transplantation - Drug Profile 152
Carboplatin + Cyclophosphamide + Etoposide + Irinotecan + Temozolomide + Vincristine - Drug Profile 155
Natural Killer Cells - Drug Profile 157
Filgrastim + Amifostine - Drug Profile 158
Rituximab - Drug Profile 159
PEP-3-KLH - Drug Profile 161
Dendritic Cell Vaccine - Drug Profile 162
ARC-100 - Drug Profile 163
ANG1007 - Drug Profile 165
Sargramostim + Telomerase 540-548 Peptide Vaccine - Drug Profile 166
DC/AAT + DC/AAT-Flu + DC/KLH - Drug Profile 167
GW572016 - Drug Profile 168
erismodegib - Drug Profile 169
Irinotecan + Temozolomide - Drug Profile 170
Bevacizumab + Camptosar - Drug Profile 171
Carboplatin + Cyclophosphamide + Etoposide + Etoposide Phosphate + Sodium Thiosulfate - Drug Profile 172
Mafosfamide - Drug Profile 174
AAV-hIFN-Beta - Drug Profile 175
Enzastaurin - Drug Profile 176
Torisel - Drug Profile 177
Palonosetron + Dexamethasone - Drug Profile 178
imatinib mesylate - Drug Profile 180
Bevacizumab + Irinotecan - Drug Profile 181
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Thiotepa + Vincristine + Peripheral Stem Cell Transplantation - Drug Profile 182
Bevacizumab - Drug Profile 184
cilengitide - Drug Profile 185
carboplatin - Drug Profile 186
Carboplatin + Cereport - Drug Profile 187
porfimer sodium - Drug Profile 188
2B3-101 - Drug Profile 189
Cisplatin + Cyclophosphamide + Etoposide + Lomustine + Vincristine + Radiation Therapy - Drug Profile 191
EGEN-001 - Drug Profile 193
Docetaxel - Drug Profile 195
Carboplatin + Cyclophosphamide + Etoposide + Sodium Thiosulfate - Drug Profile 196
VNP40101M - Drug Profile 198
Verteporfin - Drug Profile 199
Avastin + Carmustine - Drug Profile 200
Enzastaurin + Bevacizumab - Drug Profile 201
ANG1009 - Drug Profile 202
Carboplatin + Cisplatin - Drug Profile 203
LEQ-506 - Drug Profile 204
Ferumoxytol - Drug Profile 205
Dichloroacetate - Drug Profile 206
Dichloroacetate - Drug Profile 207
Vandetanib + Dasatinib - Drug Profile 208
Carboplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Vincristine - Drug Profile 209
Cyclophosphamide + Cyclosporine + Fludarabine Phosphate + Mycophenolate Mofetil + Umbilical Cord Blood Transplantation + Radiation Therapy - Drug Profile 211
Velcade + Radiation Therapy - Drug Profile 213
Dendritic cells + Imiquimod - Drug Profile 214
Misonidazole + CCNU - Drug Profile 215
Vinblastine + Sirolimus - Drug Profile 216
DepoCyt + Temozolomide - Drug Profile 217
Cyclophosphamide + Vincristine - Drug Profile 218
Filgrastim + Carboplatin + Temozolomide + Thiotepa + Peripheral Stem Cell Transplantation - Drug Profile 219
Filgrastim + Carboplatin + Temozolomide + Thiotepa + Peripheral Stem Cell Transplantation - Drug Profile 221
Paclitaxel + Cyclophosphamide + Autologous Tumor Cell Vaccine + Sargramostim + Cisplatin + Carmustine - Drug Profile 223
5-Aminolevuline Acid - Drug Profile 225
Cilengitide + Temozolomide - Drug Profile 226
Cisplatin + Lomustine + Vincristine - Drug Profile 227
cisplatin + lomustine + vincristine sulfate - Drug Profile 228
levetiracetam + pregabalin - Drug Profile 229
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile 231
tipifarnib + radiation theraphy - Drug Profile 233
tipifarnib + radiation theraphy - Drug Profile 234
vandetanib + radiation theraphy - Drug Profile 235
carboplatin + lobradimil - Drug Profile 236
Carboplatin + Etoposide + Vincristine + Radiation Therapy - Drug Profile 237
Cyclophosphamide + Etoposide + Vincristine + Radiation Therapy - Drug Profile 239
IMATINIB + Hydroxyurea - Drug Profile 241
talabostat + carboplatin - Drug Profile 242
Carboplatin + Cyclophosphamide + Etoposide + Vincristine + Doxorubicin + Cisplatin - Drug Profile 244
Carboplatin + Sodium Thiosulfate - Drug Profile 246
Combidex - Drug Profile 247
ARC-100 + Temodar - Drug Profile 248
Sunitinib - Drug Profile 250
Sunitinib - Drug Profile 251
Bortezomib + Temozolomide + Radiation therapy - Drug Profile 252
Carboplatin + Pyrazoloacridine - Drug Profile 254
Cisplatin + Lomustine + Vincristine Sulfate + Radiation Therapy - Drug Profile 255
Imatinib + Radiation Therapy - Drug Profile 257
irinotecan + temozolomide + radiation thraphy - Drug Profile 259
CCNU + Temozolomide + Radiation Therapy - Drug Profile 261
Melphalan + Mannitol - Drug Profile 262
Motexafin Gadolinium - Drug Profile 264
procarbazine + lomustine + vincristine + radiation therapy - Drug Profile 265
Cisplatin + Lomustine + Vincristine sulfate - Drug Profile 267
ABT-751 - Drug Profile 269
ABT-888 + Temozolomide - Drug Profile 270
Carboplatin + Fluorouracil + Procarbazine - Drug Profile 271
EGb761 - Drug Profile 272
Irinotecan + Temozolomide - Drug Profile 273
Pioglitazone hydrochloride - Drug Profile 275
Topotecan - Drug Profile 276
Temozolomide + Irinotecan + Bevacizumab - Drug Profile 277
MK2206 - Drug Profile 278
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 279
LBH589 - Drug Profile 280
LY2157299 - Drug Profile 281
G-CSF + Carboplatin + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine + Radiation Therapy - Drug Profile 282
G-CSF + Carboplatin + Cisplatin + Cyclophosphamide + Vincristine + Radiation Therapy - Drug Profile 284
G-CSF + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine + Radiation Therapy - Drug Profile 286
MK2206 + Paclitaxel - Drug Profile 288
PVS-30200 - Drug Profile 289
NSI-566RSC - Drug Profile 290
KX-02 - Drug Profile 292
Nifurtimox + Cyclophosphamide + Topotecan - Drug Profile 293
Cisplatin + Cyclophosphamide + Etoposide + Vincristine - Drug Profile 295
Temozolomide + Etoposide - Drug Profile 297
TTRNA-xALT + TTRNA-DCs - Drug Profile 298
Siomycin A - Drug Profile 300
VLI-01B - Drug Profile 301
PBT-519 - Drug Profile 303
Vismodegib + Temozolomide - Drug Profile 304
LB-102 - Drug Profile 305
BT2111 - Drug Profile 306
Brain Cancer Therapeutics Drug Profile Updates 307
Brain Cancer Therapeutics Discontinued Products 320
Brain Cancer Therapeutics - Dormant Products 321
Brain Cancer Product Development Milestones 328
Featured News & Press Releases 328

Appendix 334
Methodology 334
Coverage 334
Secondary Research 334
Primary Research 334
Expert Panel Validation 334
Contact Us 335
Disclaimer 335

Number of Products Under Development for Brain Cancer, H2 2012 24
Products under Development for Brain Cancer Comparative Analysis, H2 2012 25
Number of Products under Development by Companies, H2 2012 27
Number of Products under Development by Companies, H2 2012 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 34
Comparative Analysis by Late Stage Development, H2 2012 35
Comparative Analysis by Mid Clinical Stage Development, H2 2012 36
Comparative Analysis by Early Clinical Stage Development, H2 2012 37
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 38
Products under Development by Companies, H2 2012 39
Products under Development by Companies, H2 2012 (Contd..1) 40
Products under Investigation by Universities/Institutes, H2 2012 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 50
United Therapeutics Corporation, H2 2012 51
Sanofi-Aventis, H2 2012 52
Eli Lilly and Company, H2 2012 53
Novartis AG, H2 2012 54
Dong-A Pharmaceutical Co., Ltd., H2 2012 55
Nippon Shinyaku Co., Ltd., H2 2012 56
Pfizer Inc., H2 2012 57
Alfacell Corporation, H2 2012 58
Advaxis, Inc., H2 2012 59
Neuralstem, Inc., H2 2012 60
Lixte Biotechnology Holdings, Inc., H2 2012 61
Bionomics Limited, H2 2012 62
Critical Outcome Technologies Inc., H2 2012 63
Prana Biotechnology Limited, H2 2012 64
Diamyd Medical AB, H2 2012 65
e-Therapeutics plc, H2 2012 66
AngioChem Inc., H2 2012 67
Pervasis Therapeutics, Inc., H2 2012 68
PTC Therapeutics, Inc., H2 2012 69
Stemline Therapeutics, Inc., H2 2012 70
Kinex Pharmaceuticals, LLC, H2 2012 71
to-BBB technologies BV, H2 2012 72
Archer Biosciences, Inc, H2 2012 73
ArmaGen Technologies, Inc., H2 2012 74
VectorLogics, Inc., H2 2012 75
Assessment by Monotherapy Products, H2 2012 76
Assessment by Combination Products, H2 2012 77
Assessment by Stage and Route of Administration, H2 2012 80
Assessment by Stage and Molecule Type, H2 2012 83
Brain Cancer Therapeutics Drug Profile Updates 319
Brain Cancer Therapeutics Discontinued Products 332
Brain Cancer Therapeutics Dormant Products 333
Brain Cancer Therapeutics Dormant Products (Contd..1) 334
Brain Cancer Therapeutics Dormant Products (Contd..2) 335
Brain Cancer Therapeutics Dormant Products (Contd..3) 336
Brain Cancer Therapeutics Dormant Products (Contd..4) 337
Brain Cancer Therapeutics Dormant Products (Contd..5) 338
Brain Cancer Therapeutics Dormant Products (Contd..6) 339
Number of Products under Development for Brain Cancer, H2 2012 24
Products under Development for Brain Cancer - Comparative Analysis, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Investigation by Universities/Institutes, H2 2012 29
Late Stage Products, H2 2012 35
Mid Clinical Stage Products, H2 2012 36
Early Clinical Stage Products, H2 2012 37
Discovery and Pre-Clinical Stage Products, H2 2012 38
Assessment by Monotherapy Products, H2 2012 76
Assessment by Combination Products, H2 2012 77
Assessment by Route of Administration, H2 2012 78
Assessment by Stage and Route of Administration, H2 2012 79
Assessment by Molecule Type, H2 2012 81
Assessment by Stage and Molecule Type, H2 2012 82